What is Cytokinetics's free cash flow?

Cytokinetics (CYTK) reported free cash flow of -$151.39M in Q1 2026.

How has Cytokinetics's free cash flow changed year-over-year?

Cytokinetics's free cash flow decreased by 10.3% year-over-year, from -$137.28M to -$151.39M.

What is the long-term trend for Cytokinetics's free cash flow?

Over 4 years (2021 to 2025), Cytokinetics's free cash flow has grown at a 29.3% compound annual growth rate (CAGR), from -$191.39M to -$534.82M.

Cytokinetics CYTK Free cash flow

Free cash flow at other companies

Bristol-Myers SquibbBMY

$757M-55.3%

Eli LillyLLY

$3.01B+1,828%

Merck & Co.MRK

$2.93B+150%

MedtronicMDT

$2.09B+0.8%

Boston ScientificBSX

$171M-51.7%

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

See full

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

See full

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Valuation

See full

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

See full

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

See full

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Calculated from Cytokinetics’s reported figures.

−$145.5Mnet cash from operating−$5.9Mcapital expenditures=-$151.39M

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytokinetics's free cash flow?: Cytokinetics (CYTK) reported free cash flow of -$151.39M in Q1 2026.
How has Cytokinetics's free cash flow changed year-over-year?: Cytokinetics's free cash flow decreased by 10.3% year-over-year, from -$137.28M to -$151.39M.
What is the long-term trend for Cytokinetics's free cash flow?: Over 4 years (2021 to 2025), Cytokinetics's free cash flow has grown at a 29.3% compound annual growth rate (CAGR), from -$191.39M to -$534.82M.